Lorlatinib (CAS 1454846-35-5)
Alternate Names:
PF-06463922 PF06463922 PF 06463922 Lorbrena
CAS Number:
1454846-35-5
Molecular Weight:
406.40
Molecular Formula:
C21H19FN6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lorlatinib (CAS 1454846-35-5) References
- Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC. | Gemelli, M., et al. 2024. Expert Rev Anticancer Ther. 24: 347-361. PMID: 38630549
- Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line. | Sungwan, P., et al. 2024. Hum Cell. 37: 1215-1225. PMID: 38755432
- Relationship between Anaplastic Lymphoma Kinase Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study. | Noguchi, Y., et al. 2024. Oncology. 1-8. PMID: 38768582
- Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study. | Huang, Z., et al. 2024. Lung Cancer. 192: 107827. PMID: 38795459
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. | Solomon, BJ., et al. 2024. J Clin Oncol. JCO2400581. PMID: 38819031
- Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo. | Yokota, E., et al. 2024. Hum Cell. 37: 1132-1140. PMID: 38829559
- Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth. | Lai, WY., et al. 2024. Cell Death Differ.. PMID: 38858548
- Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. | Arnaoutakis, K., et al. 2024. Adv Ther.. PMID: 38916812
- Targeting lipid peroxidation-associated ferroptosis suppresses lung carcinoma progression by regulating cell cycle arrest. | Liu, X., et al. 2024. Int Immunopharmacol. 138: 112518. PMID: 38917528
- Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib. | Sato, Y., et al. 2024. Thorac Cancer.. PMID: 38924375
- Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1). | Yang, J., et al. 2024. Bioorg Chem. 150: 107590. PMID: 38955003
- Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma. | Arndt, A., et al. 2024. Oncologist.. PMID: 38960389
- Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report. | He, Q., et al. 2024. Heliyon. 10: e32030. PMID: 38961982
Inhibitor of:
FAM150A, MAGE-E1, Olr1169, Olr726, SRPK3, ZAP-70, and ZDHHC4.Activator of:
ALK, and Med19.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lorlatinib, 5 mg | sc-507437 | 5 mg | $135.00 |